Drug Trial Radar · NCT05941741
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
380
Planned (sponsor's estimate)
Start
Jan 10, 2024
Primary completion
Dec 2027
Study completion Dec 2029
Sponsor
- Lead sponsor
- Sun Yat-sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label, randomized controlled phase III clinical trial in primary diagnosed loco-regionally advanced nasopharyngeal carcinoma (NPC) patients. The purpose of this study is to evaluate the efficacy of induction chemotherapy (IC) combined with low-dose radiation and immune checkpoint inhibitor (ICI) followed by concurrent chemoradiotherapy (CCRT) versus IC+CCRT, and compare the treatment-related adverse events and quality of life in two groups.
Conditions
- Nasopharyngeal Carcinoma
- Immune Checkpoint Inhibitor
- Radiotherapy
- Chemotherapy
Interventions
Intensity Modulated Radiation TherapyRadiation
All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node), 60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions.
ChemotherapyDrug
Induction chemotherapy: gemcitabine and cisplatin, Q3W, 3 cycles Concurrent chemotherapy: cisplatin, Q3W, 2-3 cycles
Immune checkpoint inhibitorBiological
Cadonilimab: 10mg/kg, Q3W, 3 cycles
Low-dose radiotherapyRadiation
Low-dose radiotherapy will be performed to study group, with the use of IMRT.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survivalTime frame: 3 years
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Cancer Center, Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China · Not yet recruiting
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.